The high expression of RANKL within the tumor paved the way for the use of denosumab, a fully human monoclonal antibody to RANKL, as efficient treatment for GCT, reducing its lytic activity (Chawla et al., 2019; Alothman et al., 2020). Here, TNFSF11 is linked to granular cell tumor.